Idenix Pharmaceuticals LLC
(NASDAQ : IDIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.60%163.540.7%$1305.95m
LLYEli Lilly & Co. -1.93%323.651.1%$1056.02m
ABBVAbbVie, Inc. -5.84%134.381.9%$793.06m
PFEPfizer Inc. -0.75%43.830.9%$778.51m
BMYBristol-Myers Squibb Co. -0.82%71.121.0%$763.08m
MRKMerck & Co., Inc. -0.52%86.190.7%$687.90m
AZNAstraZeneca Plc -0.13%54.841.0%$411.81m
NVSNovartis AG -0.73%76.010.2%$216.26m
GSKGSK Plc 0.31%29.450.3%$214.53m
ALNYAlnylam Pharmaceuticals, Inc. -4.41%200.168.2%$210.64m
GBTGlobal Blood Therapeutics, Inc. 0.04%68.105.4%$190.73m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.21%151.220.0%$178.64m
IDXXIDEXX Laboratories, Inc. -1.81%325.803.9%$175.84m
HZNPHorizon Therapeutics Plc -1.28%61.895.4%$160.55m
NVONovo Nordisk A/S -0.74%99.650.1%$140.44m

Company Profile

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).